SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : GZMO
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: jeffbas who wrote (235)2/20/2000 12:56:00 AM
From: jeffbas   of 438
 
For the scientifically inclined, this paper underlies the current
melanoma vaccine trials in humans - "Sytemic administration of Interleukin 2 enhances the therapeutic effect of dendritic cell-based vaccines":

pnas.org

Note, in particular the Results and Discussion section statement that,
"In contrast, all mice treated with the combination of tumor lysate-pulsed DC plus IL-2 were protected from tumor growth and remained disease free". As can be seen from the associated figure,
this is a better result than obtained from tumor-lysate alone, which
I believe was the basis of earlier Phase I trials that showed tumor regression in a significant minority of patients. Of course mice are not people.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News